54.85
前日終値:
$61.11
開ける:
$61.11
24時間の取引高:
658.88K
Relative Volume:
0.68
時価総額:
$1.12B
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-37.57
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-9.11%
1か月 パフォーマンス:
-15.52%
6か月 パフォーマンス:
+6,787%
1年 パフォーマンス:
+4,548%
Nektar Therapeutics Stock (NKTR) Company Profile
名前
Nektar Therapeutics
セクター
電話
(415) 482-5300
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
54.85 | 1.24B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-26 | 開始されました | Citigroup | Buy |
| 2025-06-24 | 繰り返されました | BTIG Research | Buy |
| 2025-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-04-11 | アップグレード | Jefferies | Hold → Buy |
| 2025-03-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 開始されました | B. Riley Securities | Buy |
| 2024-12-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-04 | 開始されました | Piper Sandler | Overweight |
| 2024-09-30 | 再開されました | BTIG Research | Buy |
| 2024-06-28 | 開始されました | Rodman & Renshaw | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Underweight |
| 2023-11-09 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | アップグレード | Jefferies | Underperform → Hold |
| 2023-02-24 | ダウングレード | Jefferies | Hold → Underperform |
| 2022-08-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 再開されました | Jefferies | Hold |
| 2022-04-18 | ダウングレード | Goldman | Neutral → Sell |
| 2022-03-15 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-03-15 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-14 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-03-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-14 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-08 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 開始されました | BofA Securities | Neutral |
| 2021-06-28 | アップグレード | Stifel | Hold → Buy |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-02-22 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-09-14 | 開始されました | JP Morgan | Neutral |
| 2020-06-10 | ダウングレード | CFRA | Hold → Sell |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-04-22 | 開始されました | The Benchmark Company | Buy |
| 2020-03-30 | アップグレード | Goldman | Sell → Neutral |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-03 | アップグレード | Mizuho | Neutral → Buy |
| 2019-10-24 | 開始されました | Oppenheimer | Perform |
| 2019-10-08 | ダウングレード | Goldman | Buy → Sell |
| 2019-08-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-08-09 | ダウングレード | Jefferies | Buy → Hold |
| 2019-08-09 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-03-15 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-06-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-04-20 | 開始されました | Seaport Global Securities | Buy |
| 2018-04-13 | 再開されました | Piper Jaffray | Overweight |
| 2018-04-06 | 繰り返されました | Mizuho | Buy |
| 2018-04-02 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Nektar Therapeutics (NKTR) 最新ニュース
How robust is Nektar Therapeutics (ITH0) stock financial position2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser
Is Nektar Therapeutics stock attractive for ETFs2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
How strong dollar benefits Nektar Therapeutics (ITH0) stockTrade Signal Summary & Free Real-Time Market Sentiment Alerts - Newser
Will Nektar Therapeutics stock benefit from upcoming earnings reportsBreakout Watch & Low Drawdown Momentum Ideas - Newser
Colorectal Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeu - Barchart.com
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - The Manila Times
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - GlobeNewswire Inc.
Latex Allergy Market Covering Prime Factors and Competitive - openPR.com
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade - Finviz
Nektar Therapeutics Reveals Promising Phase 2b Trial Results - MSN
Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus
Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 - GuruFocus
Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance
Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa
Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks
Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus
Citi Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire) - Aktiellt
Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com
Nektar Therapeutics CLO Wilson sells $34,196 in shares - Investing.com
How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition - simplywall.st
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
Nektar Therapeutics stock price target raised to $121 from $99 at Jefferies - Investing.com Nigeria
Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies - StreetInsider
Assessing Nektar Therapeutics (NKTR) Valuation Following Recent Share Price Surge - simplywall.st
Nektar Therapeutics Stock Analysis and ForecastInsider Buying Signals & Stay One Step Ahead of Risk Events - earlytimes.in
Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? - Finviz
Nektar Therapeutics announces chief legal officer transition effective year-end By Investing.com - Investing.com India
Nektar Therapeutics Announces Chief Legal Officer Departure - TipRanks
Nektar Therapeutics announces chief legal officer transition effective year-end - Investing.com
Nektar Therapeutics Announces Chief Legal Officer Change - TradingView
Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma - HCPLive
Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Will Nektar Therapeutics (ITH0) stock beat Nasdaq index returns2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Nektar at Jefferies: Biologics in Focus for New Indications By Investing.com - Investing.com Australia
Nektar at Jefferies: Biologics in Focus for New Indications - Investing.com
Nektar Therapeutics (NKTR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How big funds are accumulating Nektar Therapeutics (ITH0) stockMarket Rally & Long-Term Safe Investment Ideas - newser.com
Will Nektar Therapeutics (ITH0) stock profit from fiscal stimulusWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Is Nektar Therapeutics stock attractive for passive investorsJuly 2025 EndofMonth & AI Powered Trade Plan Recommendations - newser.com
How Nektar Therapeutics (ITH0) stock trades in high volatilityMarket Risk Analysis & Safe Entry Zone Tips - newser.com
What RSI levels show for Nektar Therapeutics (ITH0) stock2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Is it time to cut losses on Nektar TherapeuticsJuly 2025 Highlights & Verified Entry Point Signals - newser.com
Nektar Therapeutics (NKTR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):